

Table S1. Baseline characteristics of patients with ovarian cancer.

Characteristic	CDCA5 expression		FOXMI expression					
	low	high	χ^2	P	low	high	χ^2	P
n	37	71			59	49		
Age(years),median,n(%)			0.041	0.839			0.037	0.847
<56	18(16.7%)	36(33.3%)			29(26.9%)	25(23.1%)		
≥56	19(17.6%)	35(32.4%)			30(27.8%)	24(22.2%)		
Menopausal, n (%)			0.083	0.773			2.379	0.123
No	12(11.1%)	25(23.1%)			24(22.2%)	13 (12%)		
Yes	25(23.1%)	46(42.6%)			35(32.4%)	36(33.3%)		
FIGO grade, n (%)			0.564	0.452			1.845	0.174
Low	5 (4.6%)	5 (4.6%)			8 (7.4%)	2 (1.9%)		
High	32(29.6%)	66(61.1%)			51(47.2%)	47(43.5%)		
FIGO stage,n(%)			0.335	0.563			0.070	0.792
I/II	9 (8.3%)	21(19.4%)			17(15.7%)	13 (12%)		
III/IV	28(25.9%)	50(46.3%)			42(38.9%)	36(33.3%)		
Residual disease (RD),n(%)			1.242	0.538			3.414	0.181
RD0, no visible disease	6 (5.6%)	12(11.1%)			13 (12%)	5 (4.6%)		
RD1, 0.1–1.0 cm	18 (16.%)	27 (25%)			25(23.1%)	20(18.5%)		
RD>1 cm	13 (12%)	32(29.6%)			21(19.4%)	24 (22.2%)		
Histology,n (%)			5.003	0.025			3.658	0.056
Serous	21(19.4%)	55(50.9%)			37(34.3%)	39(36.1%)		
Other	16(14.8%)	16(14.8%)			22(20.4%)	10 (9.3%)		
Ascites, n (%)			5.659	0.059			3.157	0.206
Negative	15(13.9%)	29(26.9%)			26(24.1%)	18(16.7%)		
Mild	13 (12%)	12(11.1%)			16(14.8%)	9 (8.3%)		
Moderate-severe	9 (8.3%)	30(27.8%)			17(15.7%)	22(20.4%)		
Tumor size (cm), n (%)			0.211	0.646			0.260	0.610
<8	16(14.8%)	34(31.5%)			26(24.1%)	24(22.2%)		
≥8	21(19.4%)	37(34.3%)			33(30.6%)	25(23.1%)		
Preoperative CA125 (U/ml), n(%)			1.280	0.258			0.534	0.465
<600	24(22.2%)	38(35.2%)			32(29.6%)	30(27.8%)		
≥600	13 (12%)	33(30.6%)			27 (25%)	19(17.6%)		
Preoperative CA153 (U/ml) ,n(%)			0.004	0.949			0.136	0.712
<28	19(17.6%)	36(33.3%)			31(28.7%)	24(22.2%)		
≥28	18(16.7%)	35(32.4%)			28(25.9%)	25(23.1%)		
Preoperative CA199(U/ml),n (%)			0.766	0.381			0.571	0.450
<37	16(14.8%)	37(34.3%)			27 (25%)	26(24.1%)		
≥37	21(19.4%)	34(31.5%)			32(29.6%)	23(21.3%)		
Preoperative CEA (U/ml),n (%)			1.640	0.200			0.136	0.712
<5	15(13.9%)	38(35.2%)			28(25.9%)	25(23.1%)		
≥5	22(20.4%)	33(30.6%)			31(28.7%)	24(22.2%)		
Intestinal metastasis,n (%)			0.087	0.768			6.055	0.014
No	13 (12%)	27 (25%)			28(25.9%)	12(11.1%)		
Yes	24(22.2%)	44(40.7%)			31(28.7%)	37(34.3%)		
Peritoneal metastasis,n (%)			0.198	0.657			2.340	0.126
No	6 (5.6%)	14 (13%)			14 (13%)	6 (5.6%)		
Yes	31(28.7%)	57(52.8%)			45(41.7%)	43(39.8%)		
Distant metastasis,n (%)			1.349	0.245			0.981	0.322
No	36(33.3%)	63(58.3%)			56(51.9%)	43(39.8%)		
Yes	1 (0.9%)	8 (7.4%)			3 (2.8%)	6 (5.6%)		